

# Shane Kavanagh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11197455/publications.pdf>

Version: 2024-02-01

21  
papers

515  
citations

687363

13  
h-index

713466

21  
g-index

22  
all docs

22  
docs citations

22  
times ranked

618  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quantifying the handprintâ€™Footprint balance into a single score: The example of pharmaceuticals. PLoS ONE, 2020, 15, e0229235.	2.5	2
2	Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections. BMC Health Services Research, 2019, 19, 393.	2.2	11
3	The public health benefit and burden of mass drug administration programs in Vietnamese schoolchildren: Impact of mebendazole. PLoS Neglected Tropical Diseases, 2018, 12, e0006954.	3.0	5
4	Human health benefits and burdens of a pharmaceutical treatment: Discussion of a conceptual integrated approach. Environmental Research, 2016, 144, 19-31.	7.5	14
5	Bowel Function After Tapentadol and Oxycodone Immediate Release (IR) Treatment in Patients With Low Back or Osteoarthritis Pain. Clinical Journal of Pain, 2013, 29, 664-672.	1.9	13
6	Long-term Effects of Galantamine on Cognitive Function in Alzheimer's Disease: A Large-Scale International Retrospective Study. Journal of Alzheimer's Disease, 2011, 27, 521-530.	2.6	19
7	Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. Clinical Therapeutics, 2010, 32, 1768-1781.	2.5	16
8	Costs of Gastrointestinal Events after Outpatient Opioid Treatment for Non-Cancer Pain. Annals of Pharmacotherapy, 2010, 44, 630-640.	1.9	47
9	Importance of Side Effects in Opioid Treatment: A Trade-Off Analysis With Patients and Physicians. Journal of Pain, 2010, 11, 1095-1108.	1.4	100
10	Long-term treatment of patients with Alzheimer's disease in primary and secondary care: results from an international survey. Current Medical Research and Opinion, 2009, 25, 3059-3068.	1.9	24
11	Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry, 2009, 24, 479-488.	2.7	64
12	Costs and cognitive disability: modelling the underlying associations. British Journal of Psychiatry, 2002, 180, 120-125.	2.8	20
13	Cognitive disability and direct care costs for elderly people. British Journal of Psychiatry, 1999, 174, 539-546.	2.8	23
14	The costs of comorbidity: Anxiety and depression. European Psychiatry, 1998, 13, 137s-137s.	0.2	0
15	The impact on general practitioners of the changing balance of care for elderly people living in institutions. BMJ: British Medical Journal, 1998, 317, 322-327.	2.3	43
16	Purchasers, providers and managed care. Current Opinion in Psychiatry, 1997, 10, 153-159.	6.3	4
17	Leaving hospital: one and two-year outcomes of long-stay psychiatric patients discharged to the community. Journal of Mental Health, 1996, 5, 245-256.	1.9	12
18	Leaving hospital II: the cost-effectiveness of community care for former long-stay psychiatric hospital patients. Journal of Mental Health, 1996, 5, 379-394.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Market Rationales, Rationing, And Rationality: Mental Health Care Reform In The United Kingdom. Health Affairs, 1995, 14, 260-268.	5.2	19
20	Elderly People with Advanced Cognitive Impairment in England: Resource Use and Costs. Ageing and Society, 1993, 13, 27-50.	1.7	40
21	Elderly people with cognitive impairment: costing possible changes in the balance of care. Health and Social Care in the Community, 1993, 1, 69-80.	1.6	28